The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Trastuzumab Triggers Phagocytic Killing of High HER2 Cancer Cells In Vitro and In Vivo by Interaction with Fcγ Receptors on Macrophages
Abstract
Trastuzumab has been used for the treatment of HER2-overexpressing breast cancer for more than a decade, but the mechanisms of action for the therapy are still being actively investigated. Ab-dependent cell-mediated cytotoxicity mediated by NK cells is well recognized as one of the key mechanisms of action for trastuzumab, but trastuzumab-mediated Ab-dependent cellular phagocytosis (ADCP) has not been established. In this study, we demonstrate that macrophages, by way of phagocytic engulfment, can mediate ADCP and cancer cell killing in the presence of trastuzumab. Increased infiltration of macrophages in the tumor tissue was associated with enhanced efficacy of trastuzumab whereas depletion of macrophages resulted in reduced antitumor efficacy in mouse xenograft tumor models. Among the four mouse FcγRs, FcγRIV exhibits the strongest binding affinity to trastuzumab. Knockdown of FcγRIV in mouse macrophages reduced cancer cell killing and ADCP activity triggered by trastuzumab. Consistently, an upregulation of FcγRIV expression by IFN-γ triggered an increased ADCP activity by trastuzumab. In an analogous fashion, IFN-γ priming of human macrophages increased the expression of FcγRIII, the ortholog of murine FcγRIV, and increased trastuzumab-mediated cancer cell killing. Thus, in two independent systems, the results indicated that activation of macrophages in combination with trastuzumab can serve as a therapeutic strategy for treating high HER2 breast cancer by boosting ADCP killing of cancer cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HER2-targeting mAbs also elicit antibody-dependent cellular phagocytosis (ADCP), involving the clearance of antibodybound tumor cells by macrophages (Shi et al., 2015), a phenomenon that may be accompanied by macrophage polarization towardanM2-like immunosuppressive phenotype (Su et al., 2018).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Shi et al., 2015
In the citing paper
“induction of ADCP of HER2-expressing cancer cells”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Shi et al., 2015
Citations
Cites
2 retracted
She, Q.-B., Chandarlapaty, S., Ye, Q., Lobo, J., Haskell, K. M., Leander, K. R., DeFeo-Jones, D., Huber, H. E., & Rosen, N. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003065 · Cited by 301 · cited 1×
“Other mechanisms of action of trastuzumab, including downregulation of HER2 expression (6) and inhibition of HER2 oncogenic signaling (2, 4), might also be involved.”
BackgroundRetractedKohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F., Czerwinski, D., Colevas, A. D., Weng, W.-K., Clarke, M. F., Carlson, R. W., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61226 · Cited by 226 · cited 1×
“Therefore, antitumor efficacy of trastuzumab in the mouse group with macrophage depletion by clodrosome might be contributed by an NK cell– mediated ADCC effect, as ADCC as a mechanism of action for trastuzumab was reported previously (27, 29).”
BackgroundRetractedInhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 1×
“Studies have shown that mice with Fcg-chain knockout (g) or knockout of individual activating FcgRs lost immune effector functions of Abs and resulted in reduced antitumor efficacy of trastuzumab (22, 32, 33).”
BackgroundNagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858 · cited 1×
“Other mechanisms of action of trastuzumab, including downregulation of HER2 expression (6) and inhibition of HER2 oncogenic signaling (2, 4), might also be involved.”
BackgroundDivergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding
Nimmerjahn, F., & Ravetch, J. V. (2005) · Science · doi:10.1126/science.1118948 · Cited by 1,037 · cited 1×
“It has been shown that FcgRIV is important in mediating the function of anticancer Ab (IgG2a) in the model of lung and liver metastases using murine melanoma cells, and in an anti-CD20 Abdependent B cell depletion model (24, 36, 37).”
BackgroundMusolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981 · cited 1×
“Clinical studies have implicated the important role of FcgRIII in trastuzumab efficacy (38), even though function of FcgRIII on NK cells is considered mainly to contribute to cancer cell killing through ADCC (39).”
BackgroundBone Marrow-Derived Macrophages (BMM): Isolation and Applications
Weischenfeldt, J., & Porse, B. (2008) · Cold Spring Harbor Protocols · doi:10.1101/pdb.prot5080 · Cited by 955 · cited 2×
“Briefly, the isolated bone marrow cells were cultured in complete RPMI 1640 medium supplemented with 10% FCS and 30% pretested conditioned medium from the L929 cell line as a source of M-CSF for 5 d (17).”
BackgroundMethodEngineered antibody Fc variants with enhanced effector function
Lazar, G. A., Dang, W., Karki, S., Vafa, O., Peng, J. S., Hyun, L., Chan, C., Chung, H. S., Eivazi, A., Yoder, S. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508123103 · Cited by 803 · cited 1×
“In this study, we demonstrated that activated macrophages readily phagocytosed trastuzumab-coated cancer cells (ADCP) and mediated Ab-dependent cancer cell killing in coculture conditions in vitro, and the results are consistent with the study reported previously (16).”
ResultFcγRIV: A Novel FcR with Distinct IgG Subclass Specificity
Nimmerjahn, F., Bruhns, P., Horiuchi, K., & Ravetch, J. V. (2005) · Immunity · doi:10.1016/j.immuni.2005.05.010 · Cited by 660 · cited 4×
“FcgRIV binds to mouse IgG2a and IgG2b with intermediate affinity, but it has no detectable binding to mouse IgG1 or IgG3 (22).”
BackgroundInfluentialThe function of Fcγ receptors in dendritic cells and macrophages
Guilliams, M., Bruhns, P., Saeys, Y., Hammad, H., & Lambrecht, B. N. (2014) · Nature Reviews Immunology · doi:10.1038/nri3582 · Cited by 639
Cited by
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033
Tumor-associated macrophages: an accomplice in solid tumor progression
Chen, Y., Song, Y., Du, W., Gong, L., Chang, H., & Zou, Z. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0568-z · Cited by 1,096
“In addition, trastuzumab, a monoclonal antibody drug used for the therapy of HER2-overexpressing breast cancer, has been found to trigger macrophage-mediated phagocytic killing of cancer cells in vitro and in vivo [96].”
BackgroundProgress in tumor-associated macrophage (TAM)-targeted therapeutics
Ngambenjawong, C., Gustafson, H. H., & Pun, S. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.010 · Cited by 840
“Clinically approved anti-cancer monoclonal antibodies such as rituximab and trastuzumab have been demonstrated to exert their therapeutic effects, primarily or in part, through macrophage-mediated ADCP [90][91].”
Clinical significance of tumor-infiltrating lymphocytes in breast cancer
Stanton, S. E., & Disis, M. L. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0165-6 · Cited by 828
Targeting macrophages in cancer immunotherapy
Duan, Z., & Luo, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00506-6 · Cited by 625
Tumor-associated macrophages in breast cancer: Innocent bystander or important player?
Qiu, S.-Q., Waaijer, S. J. H., Zwager, M. C., de Vries, E. G. E., van der Vegt, B., & Schröder, C. P. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.08.010 · Cited by 425
“In vitro, M1-like macrophages in the presence of trastuzumab were more potent in phagocytosis compared to M2-like macrophages [73].”
BackgroundDual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments
Xu, J., Ding, L., Mei, J., Hu, Y., Kong, X., Dai, S., Bu, T., Xiao, Q., & Ding, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02325-5 · Cited by 389
“…response to targeted anticancer drugs, 211 and many studies have con fi rmed that trastuzumab can trigger the phagocytosis of human epidermal growth factor receptor 2 (HER2)-positive cells by macrophages, 212,213 which suggests a potential role for TAMs in the antitumor activity of antibody therapy.”
A Comprehensive Review of HER2 in Cancer Biology and Therapeutics
Cheng, X. (2024) · Genes · doi:10.3390/genes15070903 · Cited by 243
Current progress in innovative engineered antibodies
Strohl, W. R. (2018) · Protein & Cell · doi:10.1007/s13238-017-0457-8 · Cited by 279
“Examples of antibody engineering and key early dates for the various technologies developed Type of engineering Key early date Notes or comments Example references Chimerization 1984 Mouse variable sequences fused to human constant sequences Morrison et al., 1984 Humanization 1986 Mouse CDRs in human frameworks Jones…”
InfluentialSelf-citationTrial watch: Immunogenic cell death induction by anticancer chemotherapeutics
Garg, A. D., More, S., Rufo, N., Mece, O., Sassano, M. L., Agostinis, P., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1386829 · Cited by 276
Endocytosis in cancer and cancer therapy
Banushi, B., Joseph, S. R., Lum, B., Lee, J. J., & Simpson, F. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00574-6 · Cited by 232
Cruz, E., & Kayser, V. (2019) · Biologics: Targets and Therapy · doi:10.2147/btt.s166310 · Cited by 221
“34 Additionally, trastuzumab can mediate ADCC35,36 and ADCP.26,36,37 Induction of CDC has also been documented in in vitro experi- ments, but it is thought to contribute only minimally to the anticancer effect in patients.36,38 Intrinsic alterations of the HER2 receptor involving regions associated with the binding ep…”
New immune cell engagers for cancer immunotherapy
Fenis, A., Demaria, O., Gauthier, L., Vivier, E., & Narni-Mancinelli, E. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-023-00982-7 · Cited by 203
“ADCP is also an important mechanism action for rituximab, ofatumumab, ocaratuzumab and obinutuzumab, which target B cell proteins, in chronic lymphocytic leukaemia 126 , and for the anti-HER2 antibody trastuzumab in the killing of HER2 + cancer cells, both in vitro and in vivo 127 .”
Emerging Targeted Therapies for HER2-Positive Breast Cancer
Mercogliano, M. F., Bruni, S., Mauro, F. L., & Schillaci, R. (2023) · Cancers · doi:10.3390/cancers15071987 · Cited by 194
“ADCC and ADCP, mainly performed by NK cells and macrophages, respectively, trigger an innate immune response that promotes antigen presentation and the subsequent adaptive immune response [19,198–201].”
BackgroundInfluentialImmunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Nami, B., Maadi, H., & Wang, Z. (2018) · Cancers · doi:10.3390/cancers10100342 · Cited by 190
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 160
Lu, C., Liu, Y., Ali, N. M., Zhang, B., & Cui, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1039260 · Cited by 181
Role of Fcγ receptors in HER2-targeted breast cancer therapy
Musolino, A., Gradishar, W. J., Rugo, H. S., Nordstrom, J. L., Rock, E. P., Arnaldez, F. I., & Pegram, M. D. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003171 · Cited by 144
Marra, A., Chandarlapaty, S., & Modi, S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00849-9 · Cited by 156
Garg, A. D., Romano, E., Rufo, N., & Agostinis, P. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.5 · Cited by 151
Upton, R., Banuelos, A. M., Feng, D., Biswas, T., Kao, K. S., McKenna, K. M., Willingham, S. B., Ho, P. Y., Rosental, B., Tal, M. C., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2026849118 · Cited by 137
“Recent reports have further illuminated trastuzumab ’ s ability to engage Fc-γ receptors (Fc γ R) on macrophages and promote antibody-dependent cellular phagocytosis (ADCP) (14).”
Zheng, H., Peng, X., Yang, S., Li, X., Huang, M., Wei, S., Zhang, S., He, G., Liu, J., Fan, Q., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01356-7 · Cited by 135
“Antibodies The FDA has approved a number of monoclonal antibodies for the clinical management of cancers, including rituximab (for B-cell lymphoma) [99], trastuzumab (for breast cancer) [100], and immune checkpoint inhibitors.”
BackgroundInflammation as target in cancer therapy
Marelli, G., Sica, A., Vannucci, L. E., & Allavena, P. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.05.007 · Cited by 133
Influence of immunoglobulin isotype on therapeutic antibody function
Beers, S. A., Glennie, M. J., & White, A. L. (2016) · Blood · doi:10.1182/blood-2015-09-625343 · Cited by 125
Tsao, L.-C., Crosby, E. J., Trotter, T. N., Agarwal, P., Hwang, B.-J., Acharya, C. R., Shuptrine, C. W., Wang, T., Wei, J.-P., Yang, X. Y., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.131882 · Cited by 124
“Inconsistent reports about the role of ADCP exist, with a recent study demonstrating the ability of trastuzumab to elicit ADCP (16), while another study suggests that trastuzumab-mediated ADCP triggers macrophage immunosuppression in HER2+ BC (17).”
BackgroundResultCao, X., Chen, J., Li, B., Dang, J., Zhang, W., Zhong, X., Wang, C., Raoof, M., Sun, Z., Yu, J., et al. (2022) · Science Advances · doi:10.1126/sciadv.abl9171 · Cited by 126
“While the involvement of therapeutic antibodies in inducing ADCP for cancer cell elimination has been investigated in individual cancer models in previous studies ( 20 , 21 , 31 – 35 ), whether ADCP functions as a generally applicable mechanism for multiple cancers has not been well established.”
Sagwal, S. K., Pasqual-Melo, G., Bodnar, Y., Gandhirajan, R. K., & Bekeschus, S. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1221-6 · Cited by 125
Peng, H., Chen, B., Huang, W., Tang, Y., Jiang, Y., Zhang, W., & Huang, Y. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b03756 · Cited by 116
HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy
Triulzi, T., Forte, L., Regondi, V., Modica, M. D., Ghirelli, C., Carcangiu, M. L., Sfondrini, L., Balsari, A., & Tagliabue, E. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1512942 · Cited by 110
Li, H., Somiya, M., & Kuroda, S. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120601 · Cited by 107
Reddy, S. M., Reuben, A., Barua, S., Jiang, H., Zhang, S., Wang, L., Gopalakrishnan, V., Hudgens, C. W., Tetzlaff, M. T., Reuben, J. M., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0619 · Cited by 106
“the importance of this mechanism in addition to NK cells in mediating improved outcomes (50, 51).”
BackgroundPrognostic and predictive role of tumour-associated macrophages in HER2 positive breast cancer
Honkanen, T. J., Tikkanen, A., Karihtala, P., Mäkinen, M. J., Väyrynen, J. P., & Koivunen, J. P. (2019) · Scientific Reports · doi:10.1038/s41598-019-47375-2 · Cited by 103
Gui, X., Deng, M., Song, H., Chen, Y., Xie, J., Li, Z., He, L., Huang, F., Xu, Y., Anami, Y., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0036 · Cited by 100
“To verify that Fc-mediated immune function is one of the mechanisms for anti-AML activity of h128-3, we generated Fc-mutated h128-3 (h128-3-N297A), which is defective in ADCC and ADCP, by abolishing the binding of h128-3 to FcgRson immune cells (31).”
BackgroundSelf-citationMacrophage-Mediated Trogocytosis Leads to Death of Antibody-Opsonized Tumor Cells
Velmurugan, R., Challa, D. K., Ram, S., Ober, R. J., & Ward, E. S. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0335 · Cited by 100
“7 cells phagocytose trastuzumab-opsonized BT-474 cells (44).”
Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab
Kurdi, A. T., Glavey, S. V., Bezman, N., Jhatakia, A., Guerriero, J. L., Manier, S., Moschetta, M., Mishima, Y., Roccaro, A. M., Detappe, A., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0998 · Cited by 105
Metabolic reprograming of tumor-associated macrophages
Puthenveetil, A., & Dubey, S. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-2037 · Cited by 105
“Examples include rituximab which promotes phagocytic activity of macrophages thus inhibiting tumor development (181), and trastuzumab used for HER2-overexpressing breast cancer therapy which triggers the phagocytic activity of macrophages both in-vitro and in-vivo (182).”
BackgroundEarly immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit
Triulzi, T., Regondi, V., De Cecco, L., Cappelletti, M. R., Di Modica, M., Paolini, B., Lollini, P. L., Di Cosimo, S., Sfondrini, L., Generali, D., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0318-0 · Cited by 94
Targeting tumor‐associated macrophages: A potential treatment for solid tumors
Chen, Y., Jin, H., Song, Y., Huang, T., Cao, J., Tang, Q., & Zou, Z. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30139 · Cited by 97
“Promoting macrophage phagocytic activity is achieved by inhibiting the CD47/ SIRP‐α pathways with inhibitors or monoclonal antibodies, and promoting antibody‐dependent cellular phagocytosis (ADCP).”
BackgroundInfluentialHarnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy
Chen, S., Lai, S. W. T., Brown, C. E., & Feng, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.635173 · Cited by 91
“Furthermore, ADCP is one of the cytotoxic mechanisms used by rituximab, ofatumumab, ocaratuzumab, and obinutuzumab, which are human monoclonal antibodies targeting CD20, a B cell surface protein, in chronic lymphocytic leukemia (28), as well as trastuzumab, an anti-HER2 monoclonal antibody that triggers phagocytic cyt…”
BackgroundLi, F., Ulrich, M. L., Jonas, M., Stone, I. J., Linares, G., Zhang, X., Westendorf, L., Benjamin, D. R., & Law, C. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0019 · Cited by 91
“growth factor receptor 2 (HER2)-positive cells (19, 20).”
BackgroundTargeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era
Mandó, P., Rivero, S. G., Rizzo, M., Pinkasz, M., & Levy, E. M. (2021) · The Breast · doi:10.1016/j.breast.2021.08.007 · Cited by 90
Vivekanandhan, S., & Knutson, K. L. (2022) · Cancers · doi:10.3390/cancers14205115 · Cited by 88
“In murine and in vitro human cell culture models, trastuzumab activates phagocytic killing through murine FcγRIV and human FCγRIII, respectively [97].”
BackgroundSilencing of SIRPα enhances the antitumor efficacy of CAR-M in solid tumors
Zhang, H., Huo, Y., Zheng, W., Li, P., Li, H., Zhang, L., Sa, L., He, Y., Zhao, Z., Shi, C., et al. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01220-3 · Cited by 78
Beck, J. D., Diken, M., Suchan, M., Streuber, M., Diken, E., Kolb, L., Allnoch, L., Vascotto, F., Peters, D., Beissert, T., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.013 · Cited by 66
Nakamura, A., Grossman, S., Song, K., Xega, K., Zhang, Y., Cvet, D., Berger, A., Shapiro, G., & Huszar, D. (2022) · Blood · doi:10.1182/blood.2021014267 · Cited by 77
Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity
Dagher, R., Kumar, V. V., Copenhaver, A. M., Gallagher, S., Ghaedi, M., Boyd, J., Newbold, P., Humbles, A. A., & Kolbeck, R. (2021) · European Respiratory Journal · doi:10.1183/13993003.04306-2020 · Cited by 72
The Impact of FcγRI Binding on Immuno-PET
Vivier, D., Sharma, S. K., Adumeau, P., Rodríguez, C. M. A., Fung, K., & Zeglis, B. M. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.223636 · Cited by 72
“Furthermore, trastuzumab has been shown to recruit immune effector cells via interactions with FcgR as part of its therapeutic mechanism (24).”
BackgroundHarnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs
Chenoweth, A. M., Wines, B. D., Anania, J. C., & Hogarth, P. M. (2020) · Immunology and Cell Biology · doi:10.1111/imcb.12326 · Cited by 68
“IgG1 is the predominant subclass used in the development of cytotoxic mAbs where induction of an activation-type response, ADCC or phagocytosis, is considered desirable.(45,76,77) Cytotoxic mAb cancer therapeutics can control disease”
BackgroundLeone, P., Lernia, G. D., Solimando, A. G., Cicco, S., Saltarella, I., Lamanuzzi, A., Ria, R., Frassanito, M. A., Ponzoni, M., Ditonno, P., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1486949 · Cited by 66
“In particular, angiogenesis promotes EC to express on their surface the αvintegrins that facilitate the growth and survival of nascent vessels and at the same time favors the phagocytic ability of EC.20 The type I and II IFN released in the microenvironment during pathological circumstances enhances the expression of…”
BackgroundAntibody‐mediated phagocytosis in cancer immunotherapy
Wagoner, C. M. V., Rivera‐Escalera, F., Jaimes‐Delgadillo, N. C., Chu, C. C., Zent, C. S., & Elliott, M. R. (2023) · Immunological Reviews · doi:10.1111/imr.13265 · Cited by 58
“80 In contrast, depletion of NK cells or neutrophils in SCID-beige tumor-bearing mice did not prevent the therapeutic efficacy of 4D5-IgG2a mAb treatment.”
BackgroundMethodInfluentialImmunotherapy in breast cancer: An introduction
Disis, M. L., & Stanton, S. E. (2017) · The Breast · doi:10.1016/j.breast.2017.01.013 · Cited by 58
“As trastuzumab induces antibody dependent cell mediated cytotoxicity and can significantly increase IFN-g production by natural killer (NK) cells, the antibody is modulating the environment to begin to support Type I T-cells [20,21].”
BackgroundThe effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
Maadi, H., Nami, B., Tong, J., Li, G., & Wang, Z. (2018) · BMC Cancer · doi:10.1186/s12885-018-4143-x · Cited by 58
Han, H., Li, S., Chen, T., Fitzgerald, M., Liu, S., Peng, C., Tang, K. H., Cao, S., Chouitar, J., Wu, J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1526 · Cited by 57
“Trastuzumab (antibody part of T-DM1) was proved to trigger antigen-dependent cellular phagocytosis (ADCP) by interacting with Fcg receptors on macrophages (29).”
Anti-Tumor Strategies by Harnessing the Phagocytosis of Macrophages
Li, S., Guo, Y.-L., Tian, J.-W., Zhang, H., Li, R., Gong, P., & Yu, Z. (2023) · Cancers · doi:10.3390/cancers15102717 · Cited by 51
“Both of them are now proven to induce ADCP and tumor cell death [163,164].”
BackgroundKabel, A. M., & Elkhoely, A. A. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.06.033 · Cited by 51
Ni, Y., Tsang, J. Y., Shao, Y., Poon, I. K., Tam, F. K. Y., Shea, K.-H., & Tse, G. M.-K. (2022) · The Oncologist · doi:10.1093/oncolo/oyab063 · Cited by 47
Laengle, J., Kabiljo, J., Hunter, L., Homola, J., Prodinger, S., Egger, G., & Bergmann, M. M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000195 · Cited by 47
Ye, Z.-H., Yu, W., Huang, M., Chen, J., & Lu, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.12.016 · Cited by 44
FcγR requirements leading to successful immunotherapy
Dahal, L. N., Roghanian, A., Beers, S. A., & Cragg, M. S. (2015) · Immunological Reviews · doi:10.1111/imr.12342 · Cited by 45
“The importance of activatory FccR-expressing macrophages to target cell deletion in other solid tumor settings has also been established for the antiHer2 mAb trastuzumab in solid cancer models (64, 65).”
BackgroundMacrophage-Based Combination Therapies as a New Strategy for Cancer Immunotherapy
Tian, L., Lei, A., Tan, T., Zhu, M., Zhang, L., Mou, H., & Zhang, J. (2021) · Kidney Diseases · doi:10.1159/000518664 · Cited by 42
Oh, K.-S., Nam, A., Bang, J., Jeong, Y., Choo, S. Y., Kim, H. J., Lee, S. I., Kim, J., Yoon, J., Kim, T.-Y., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01893-3 · Cited by 39
Macrophages as a Potential Immunotherapeutic Target in Solid Cancers
Mishra, A. K., Banday, S., Bharadwaj, R., Ali, A., Rashid, R., Kulshreshtha, A., & Malonia, S. K. (2022) · Vaccines · doi:10.3390/vaccines11010055 · Cited by 39
Persano, S., Vicini, F., Poggi, A. D., Fernandez, J. L. C., Rizzo, G. M. R., Gavilán, H., Silvestri, N., & Pellegrino, T. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101668 · Cited by 37
“Additionally, innate immune cells not only sense cancer cells and initiate adaptive immune responses, but they can also exert an effector response through specific mechanisms, such as phagocytosis for macrophages and natural cytotoxicity for natural killer (NK) cells [21,22].”
BackgroundDuan, N., Hua, Y., Yan, X., He, Y., Zeng, T., Gong, J., Fu, Z., Li, W., & Yin, Y. (2024) · Advanced Science · doi:10.1002/advs.202309424 · Cited by 37
Al-Omar, M. S., Jabir, M. S., Karsh, E. H., Kadhim, R. J., Sulaiman, G. M., Taqi, Z. J., Khashan, K. S., Mohammed, H. A., Khan, R. A., & Mohammed, S. A. A. (2021) · Nanomaterials · doi:10.3390/nano11061382 · Cited by 35
“, trastuzumab [23] which is known to increase infiltration of macrophages into the tumor tissue with enhanced anti-cancer efficacy, have been suggested to serve as a therapeutic strategy toward enhanced killings of cancer cells.”
BackgroundTargeting the complexity of ERBB2 biology in gastroesophageal carcinoma
Augustin, J., Soussan, P., & Bass, A. J. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.08.001 · Cited by 37
Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host
Modica, M. D., Tagliabue, E., & Triulzi, T. (2017) · Disease Markers · doi:10.1155/2017/7849108 · Cited by 35
“AntiHER2 increased the percentage of systemic and tumorinfiltrating macrophages in BT474 xenografts, and their depletion prior to trastuzumab treatment by clodrosome significantly impaired its ability to inhibit tumor growth [24].”
BackgroundRoles and new Insights of Macrophages in the Tumor Microenvironment of Thyroid Cancer
Liu, Q., Sun, W., & Zhang, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.875384 · Cited by 36
“Trastuzumab blocks the attachment of human EGF to Her2 by attaching itself to Her2 and mediate macrophage killing of Her-2 overexpressing in breast cancer cells (Shi et al., 2015).”
BackgroundVicencio, J. M., Evans, R., Green, R., An, Z., Deng, J., Treacy, C. A., Mustapha, R., Monypenny, J., Costoya, C., Lawler, K., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04701-3 · Cited by 35
Self-citationChen, W., Bao, L., Ren, Q., Zhang, Z., Yi, L., Lei, W., Yang, Z., Lu, Y., You, B., You, Y., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01621-9 · Cited by 33
“SCARB1 ’ s prognostic signi fi cance was determined using Kaplan-Meier analysis.”
MethodTargeting CD47 as a Novel Immunotherapy for Breast Cancer
Chen, C., Wang, R., Chen, X., Hou, Y., & Jiang, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.924740 · Cited by 34
Alsaid, H., Skedzielewski, T., Rambo, M. V., Hunsinger, K., Hoang, B. Q., Fieles, W. E., Long, E. R., Tunstead, J. R., Vugts, D. J., Cleveland, M., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176075 · Cited by 32
Wege, A. K., Weber, F., Kroemer, A., Ortmann, O., Nimmerjahn, F., & Brockhoff, G. (2016) · Oncotarget · doi:10.18632/oncotarget.13159 · Cited by 32
Sun, J., Lei, L., Tsai, C., Wang, Y., Shi, Y., Ouyang, M., Lu, S., Seong, J., Kim, T., Wang, P., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00569-6 · Cited by 32
Self-citationSevieri, M., Mazzucchelli, S., Barbieri, L., Garbujo, S., Carelli, S., Bonizzi, A., Rey, F., Recordati, C., Recchia, M., Allevi, R., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106934 · Cited by 30
ADCC: the rock band led by therapeutic antibodies, tumor and immune cells
Vincken, R., Armendáriz-Martínez, U., & Ruiz-Sáenz, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1548292 · Cited by 32
Engineering choroid plexus-on-a-chip with oscillatory flow for modeling brain metastasis
Lim, J., Rhee, S., Choi, H., Lee, J., Kuttappan, S., Nguyen, T. T., Choi, S., Kim, Y., & Jeon, N. L. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100773 · Cited by 30
Bruni, S., Mauro, F. L., Proietti, C. J., Russo, R. I. C., Rivas, M. A., Inurrigarro, G., Dupont, A., Rocha, D., Fernández, E. A., Deza, E. G., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005325 · Cited by 31
Targeting phagocytosis checkpoints for cancer immunotherapy
Veillette, A., Li, J., Galindo, C. C., Davidson, D., & Tang, Z.-H. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00893-w · Cited by 31
“However, it is increasingly evident that ADCP is largely responsible for their therapeutic efficacy 23,85,89,90 .”
InfluentialPalladini, A., Nicoletti, G., Lamolinara, A., Dall’Ora, M., Balboni, T., Ianzano, M. L., Laranga, R., Landuzzi, L., Giusti, V., Ceccarelli, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17088 · Cited by 26
“We used non-transgenic mice to avoid the interference with endogenous mammary carcinogenesis of transgenic mice even if immune response of non-transgenic mice could influence the effect of trastuzumab [25, 26].”
MethodDreyer, T. F., Kuhn, S. P., Stange, C., Heithorst, N., Schilling, D., Jelsma, J., Sievert, W., Seitz, S., Stangl, S., Hapfelmeier, A., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0327 · Cited by 23
“macrophages also express CX3CR1 and facilitate antibody-dependent cellular phagocytosis (32, 33), we determined their intratumoral accumulation.”
BackgroundNMAAP1 Expressed in BCG-Activated Macrophage Promotes M1 Macrophage Polarization
Liu, Q., Tian, Y., Zhao, X., Jing, H., Xie, Q., Li, P., Li, D., Yan, D., & Zhu, X. (2015) · Molecules and Cells · doi:10.14348/molcells.2015.0125 · Cited by 25
Estupina, P., Fontayne, A., Barret, J.-M. M., Kersual, N., Dubreuil, O., Blay, M. L., Pichard, A., Jarlier, M., Pugnière, M., Chauvin, M. Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15715 · Cited by 23
“This can be explained by the fact that human IgG1 exhibit the strongest binding to murine FcγRIV expressed on murine macrophages [52] and ADCP certainly contributes to 3C23K in vivo efficacy and might compensate at least partially the lack of activation of murine NK cells (Figure 3).”
BackgroundBloom, M. J., Jarrett, A. M., Triplett, T., Syed, A., Davis, T., Yankeelov, T. E., & Sorace, A. G. (2020) · BMC Cancer · doi:10.1186/s12885-020-06868-4 · Cited by 23
“Although a xenograft model was used in this study, murine macrophages do respond to trastuzumab (primarily through the FcγIV receptor [55]) and no significant differences in macrophage quantities or phenotypes were observed between spleens of Day 4 control and treated mice, showing immune response was directly tumor a…”
Cytotoxic IgG: Mechanisms, functions, and applications
Wöhner, M., & Nimmerjahn, F. (2025) · Immunity · doi:10.1016/j.immuni.2025.05.008 · Cited by 22
Reprogramming of pancreatic adenocarcinoma immunosurveillance by a microbial probiotic siderophore
Chaib, M., Hafeez, B. B., Mandil, H., Daria, D., Pingili, A. K., Kumari, S., Sikander, M., Kashyap, V. K., Chen, G., Anning, E., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-04102-4 · Cited by 24
Nicolini, A., Ferrari, P., Silvestri, R., & Gemignani, F. (2024) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2024.01.004 · Cited by 24
Noh, M., Kim, S. S., Kim, Y. J., Jung, T., Jung, S., Rhee, J. H., Lee, J.-H., Lee, J. S., Cho, J.-H., Moon, K., et al. (2021) · Cancers · doi:10.3390/cancers13194895 · Cited by 22
“Antibody-dependent cell phagocytosis mediated by macrophages has been reported to be the main cause of the effectiveness of trastuzumab, a HER2-targeting antibody [43].”
BackgroundKhilar, S., Dembinska-Kenner, A., Hall, H., Syrmos, N. C., Ligarotti, G. K. I., Plaha, P., Apostolopoulos, V., Chibbaro, S., Barbagallo, G. M. V., & Ganau, M. (2025) · Brain Sciences · doi:10.3390/brainsci15020136 · Cited by 22
Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies
Osborn, G., Stavraka, C., Adams, R., Sayasneh, A., Ghosh, S., Montes, A., Lacy, K. E., Kristeleit, R. S., Spicer, J. F., Josephs, D. H., et al. (2021) · Clinical & Experimental Immunology · doi:10.1093/cei/uxab020 · Cited by 22
Disis, M. L., Corulli, L. R., Gad, E. A., Koehnlein, M. R., Cecil, D. L., Senter, P. D., Gardai, S. J., & Okeley, N. M. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0500 · Cited by 21
Zhu, X., Ding, Y., Yu, Y., Wang, M., Zhou, W., Wang, J., Zhu, X., Zhang, H., Wang, M., Chai, K., et al. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04196-9 · Cited by 21
Target cell adhesion limits macrophage phagocytosis and promotes trogocytosis
Rollins, K., Fiaz, S., Datta, I., & Morrissey, M. A. (2025) · The Journal of Cell Biology · doi:10.1083/jcb.202502034 · Cited by 20
Impact of Immune Cell Heterogeneity on HER2+ Breast Cancer Prognosis and Response to Therapy
Perrone, M., Talarico, G., Chiodoni, C., & Sangaletti, S. (2021) · Cancers · doi:10.3390/cancers13246352 · Cited by 22
“The binding of trastuzumab with FcγR establishes the efficacy of therapy activating the phagocytic activity of macrophages [88,89].”
BackgroundRothwell, W. T., Bell, P. L., Richman, L. K., Limberis, M. P., Tretiakova, A. P., Li, M., & Wilson, J. M. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0363 · Cited by 20
“The effector functions of trastuzumabhave beenwidely studied (28, 29).”
BackgroundCAR-T with License to Kill Solid Tumors in Search of a Winning Strategy
Sacchetti, B., Botticelli, A., Pierelli, L., Nuti, M., & Alimandi, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081903 · Cited by 20
Flow cytometry-based assessment of direct-targeting anti-cancer antibody immune effector functions
Miller, M. L., & Finn, O. J. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.07.026 · Cited by 20
“, 2004) and an important therapeutic mechanism for trastuzumab, daratumumab (anti-CD38) and elotuzumab (anti-SLAMF7) (Kurdi et al., 2018; Overdijk et al., 2015; Shi et al., 2015; Yin et al., 2018).”
BackgroundSortilin‐related receptor is a druggable therapeutic target in breast cancer
Al‐Akhrass, H., Pietilä, M., Lilja, J., Vesilahti, E., Anttila, J. M., Haikala, H. M., Munne, P., Klefström, J. T., Peuhu, E., & Ivaska, J. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13106 · Cited by 19
Peng, J., Zhu, Q., Peng, Z., Chen, Z., Liu, Y.-T., & Liu, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1049518 · Cited by 19
“It is proposed that activation of macrophages andNK cells can strengthen the anti-cancer efficacy of trastuzumab and other Ab immunotherapies by enhancing ADCP and ADCC, demonstrating that targeted effects are secondary to immune effects (12, 13).”
Background
Metadata
- Authors
- Shi, Y., Fan, X., Deng, H., Brezski, R. J., Rycyzyn, M., Jordan, R. E., Strohl, W. R., Zou, Q., Zhang, N., & An, Z.
- Affiliations
- Army Medical University (CN)
- Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (US)
- Janssen Research & Development (United States) (US)
- Corresponding author
- Shi, Yun
- Fan, Xuejun
- Deng, Hui
- Zhang, Ningyan
- An, Zhiqiang
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-05-01
- Volume
- 194
- Issue
- 9
- Pages
- 4379-4386
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1589766395
- Cited by
- 195
- References
- 40
- Citations by year
- 2026: 9 · 2025: 18 · 2024: 22 · 2023: 19 · 2022: 27 · 2021: 23 · 2020: 20 · 2019: 16 · 2018: 13 · 2017: 19 · 2016: 6 · 2015: 3
- FWCI
- 11.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- trastuzumab, HER2-positive breast cancer, antibody-dependent cellular phagocytosis, macrophages, Fc gamma receptor, FcγRIV, FcγRIII, interferon-gamma, macrophage activation, tumor-associated macrophages, phagocytic killing, antitumor immunity
- MeSH terms
- Trastuzumab, Animals, Antibody-Dependent Cell Cytotoxicity, Antineoplastic Agents, Cytotoxicity, Immunologic, Disease Models, Animal, Humans, Macrophages, Neoplasms, Phagocytosis, Gene Expression, Receptors, IgG, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, Cell Line, Tumor, Mice, Antibodies, Monoclonal, Humanized, Heterografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.